Lv2
168 积分 2024-01-18 加入
Ulcerative Colitis in Adults
19天前
已完结
Su1732 GUSELKUMAB INDUCTION RESTORES INTESTINAL IMMUNE HOMEOSTASIS AND PROMOTES EPITHELIAL REPAIR IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
19天前
已关闭
Fr532 THE EFFECT OF GUSELKUMAB INDUCTION THERAPY ON INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: WEEK 12 RESULTS FROM THE PHASE 2 GALAXI 1 STUDY
19天前
已完结
Trends in utilization of advanced therapies in patients with inflammatory bowel diseases in the USA, 2021-2025
19天前
已完结
Etrasimod as induction and maintenance treatment for patients with moderately to severely active ulcerative colitis in East Asia (ENLIGHT UC): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study
19天前
已完结
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
19天前
已完结
IL-23 inhibition for chronic inflammatory disease
19天前
已完结
Vedolizumab for the Treatment of IBD: A Selective Therapeutic Approach Targeting Pathogenic a4b7 Cells
19天前
已完结
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies
19天前
已完结
Strategies for targeting cytokines in inflammatory bowel disease
19天前
已完结
皖公网安备34019202002308
